Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome

BACKGROUND: CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological...

Descripción completa

Detalles Bibliográficos
Autores principales: Elnaghi, Khaled Abd Elaziz Ahmed, Alghanmi, Hosam Ali, Elsamany, Shereef Ahmed, Almarzoki, Fathia, Elsafty, Mohamed, Jaffal, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473893/
https://www.ncbi.nlm.nih.gov/pubmed/37664544
http://dx.doi.org/10.1155/2023/8994954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473893/
https://www.ncbi.nlm.nih.gov/pubmed/37664544
http://dx.doi.org/10.1155/2023/8994954

Ejemplares similares